4Ammonium Biotech

Company snapshot

4Ammonium Biotech develops new drug discovery technologies addressing unmet medical needs.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for 4Ammonium Biotech. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for 4Ammonium Biotech.

1. Jun 8, 2026 Clinical update

   CTX-187-101 — Phase 1

View all clinical trial activity →

• What is 4Ammonium Biotech?

  Centauri Biotech SL is a biotech organization headquartered in EU. Primary therapeutic focus areas include Bacterial Infection. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO

• Is 4Ammonium Biotech publicly traded?

  4Ammonium Biotech appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does 4Ammonium Biotech develop or market?

  We link 2 drug profile(s) where 4Ammonium Biotech is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/centauri-biotech-sl#company-drugs.

• What are the latest developments for 4Ammonium Biotech?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does 4Ammonium Biotech focus on?

  4Ammonium Biotech focuses on Bacterial Infection based on our analysis of their pipeline programs and drug development activities.